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The present study describes the synthesis and anticancer evaluation of certain substituted rac-(2S)-2-[(R)-[(4-
substitutedphenyl){[4-(4-substitutedphenyl)-1,3-thiazol-2-yl]amino}methyl]cyclohexanone derivatives. The in vitro anti-
cancer assay indicating substituted β-amino carbonyl derivatives 4g and 4r are particularly active in both tests (HCT116 and 
H1299). The 4f, 4o, and 4t are the least functioning; 4m and 4n are marginally active; 4b and 4c are more cytotoxic when 
the growth inhibition percent is compared with standard drugs Camptothecin (CPT.), Acyclovir (ACV), Cisplatin (CDDP.), 
Vinblastine (VBL) and Trichothecene (TCT.). Among them, 2-((4-p-tosylthiazol-2-ylamino)(4-hydroxyphenyl)methyl) 
cyclohexanone 4u exhibits selective cytotoxicities for IC50 µg/mL against HCT116 and H1299, respectively. Simulation of 
virtually designed 21 compounds has been studied for active binding sites of Crystal Structure of the Cancer Genomic DNA 
Mutator APOBEC3B (PDB ID- 5CQD) enzyme using molecular modelling of protein-ligand interactions. The in-depth 
sequencing studies reveal that the involvement of APOBEC3B in cancer mutagenesis. For comparison, the binding 
behaviour of known standard drugs has also studied. The new SwissADME web utensil that gives free access to a pool of 
quick yet reliable analytical models is presented for physicochemical properties, pharmacokinetics, drug-likeness, and 
medicinal chemistry. Among them, in-house capable technique, for example, BOILED-Egg, iLOGP, and Bioavailability 
Radar, are readily available on the web. 
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bioavailability radar 
The principal aim of our effort is the discovery of 
novel cytotoxic and anticancer agents with fewer side 
effects of standard drugs (Figure 1). The three main 
treatments of neoplastic diseases comprise surgery, 
radiotherapy, and chemotherapy; this last one is the 
most limited, with a rate value of 5-10% of total 
healing. There is numeral difficulty with the safety 
profile and efficacy of chemotherapeutic agents.  
The attempts to create a new drug, which can be 
used further in the treatment of any disease is a 
formidable challenge. Many failures accompany 
development. It is always necessary to have a lot of 
creativity, intelligence, and overall good team work 
for better results1. 
Cytotoxic primarily affects the rapidly dividing 
cells, so it does not target the cancer cells, which 
specified in the resting phase. Finally, cytotoxic are 
associated with a high incidence of adverse effects. 
The typical examples consist of bone marrow 
suppression, alopecia, mucositis, nausea, and 
vomiting. Several publications reported on Mannich 
ketones as potential cytotoxins2-5. 
Some Mannich bases synthesized from thiazole or 
its derivatives containing aromatic or heterocyclic 
rings. It was estimated that at least 35% of β-amino 
carbonyl derivatives related articles are published in 
pharmaceutical journals. They are known through use 
in polymers, resins, the surface at active agents6, 
detergent additives7 antioxidants, and diuretic8.  
They have a broad range of biological activities, 
including antipsychotic9, oxytocin10, anticonvulsant11, 
centrally acting muscle relaxant12, anticancer13,14, 
antimalarial15, antiviral16, anti-tubercular, anti-
bacterial and anti-fungal17. Furthermore, β-amino 




carbonyl derivatives of various bioactive compounds 
have been prepared as prodrugs utilizing 
overwhelming some boundaries. 
The synthesis of asymmetric Mannich reaction is 
one of the most critical results in the formation of C-C 
bonds in the simulated organic chemistry used during 
the construction of enantiomerically augmented 
nitrogenous molecules and their derivatives. The 
development of asymmetric Mannich reaction has 
been encouraged by a wide variety of natural products 
and drugs possessing optically active, nitrogen-
containing molecules, which have attracted attention 
from synthetic chemists and the pharmaceutical 
industry18-23. To support the above study, we have to 
carry out the in vitro anticancer activity of the 
synthesized compounds against HCT116 and  
H1299 cancer cell lines with the help of  
Dr D. P. Manivasakam, Director, Biology Indus 
Pharmaceuticals 25 Olympia Avenue Suite K-600, 
Woburn, MA, USA. 
For the additional support to study, we have carried 
out the computational docking against the Cancer 
Genomic DNA Mutator APOBEC3B (PDB ID- 
5CQD). A few years ago, scientists discovered a 
distinctive mutagen that poses in our cells: APOBEC, 
a protein that habitually functions as a preserving 
agent against viral infection. APOBEC3B is a 
member of the astronomical family of zinc-dependent 
DNA deaminases that to adherent the cytosine that 
works typically as a nuclear-localized restriction 
factor of DNA-based pathogens bases into uracil in 
single-stranded DNA and RNA24,25. APOBEC is a 
useful yet fatal, intrinsic cellular protein. Typically 
meant to fight viruses, it has only the power of 
modifying single-stranded DNA. Human double-
stranded DNA, therefore, should not be altered. But 
scientists observed that mutations brought by 
APOBEC found in many tumorous cells, throughout 
the genome26. The APOBEC3B mutagenesis accounts 
for the most clustered and dispersed cytosine 
deamination that causes mutation in cancer. The cause 
of the disease is because of abnormal cell growth, 
which docks DNA mutations, electrifying during the 
DNA replication process. If the regular miscue takes 
place without having any deadly effect on the 
organism, a specific part of the genome may be 
affected by which causes the accumulation of the 
mutant cell, which then enters the body. Today 
geneticist has conceived how APOBEC takes 
supremacy of a weakness in our DNA approximation 
process to check mutations in our genome27. 
Notwithstanding the above computational 
examination, we additionally utilize advance and new 
methodology, i.e., Swiss absorption, distribution, 
metabolism, and excretion study. Swiss ADME is an 
excellent and exhaustive site kept running by the 
Swiss foundation of bioinformatics (SIB), which 
gives bioinformatics administrations and assets to 
researchers around the world. SIB has more than 65 
bioinformatics research gatherings and 800 
researchers from the real Swiss schools of advanced 
education and research institute. Swiss ADME 
 
 
Figure 1 — Molecular structure of the standard drugs 
 




empowers the appraisal of ADME parameters of 
medication applicants and small molecules and gives 
data that permits early hazard evaluation in the drug 
improvement process. Eminently, swissADME 
provides a stage to evaluate Lipinski's rule of five28 
for medication resemblance of oral bioavailability. 
Drug-likeness is an unpredictable equalization of 
molecular properties and structural features that 
decide if an unfamiliar molecule resembles the known 
drug. These molecular properties incorporate 
hydrophobicity, electronic dispersion, and hydrogen 
bonding attributes molecular size and adaptability. 
SwissADME includes the 'BOILED-Egg' assessment29 
that foresee gastrointestinal captivation (HIA) and 
efflux/maintenance by P-glycoprotein (Pgp). Also,  
the blood-brain barrier (BBB) infiltration and 
Cytochrome P450 (CYP) enzyme substrate-restraint 
expectation can make. 
Overall, these in vitro and computational studies 
provide a framework for further mechanistic studies 
and the development of novel anti-cancer drugs to 
inhibit this enzyme. Among these methods, docking 
has been used widely in drug designing for cancer30,31 
dampen tumour evolution, and minimize adverse 
outcomes such as drug resistance and metastasis. So, 
it better to limit the present study to some selected 
cancer macromolecules. The role of these 
macromolecules well studied by different scientists 
from time to time32,33, and their inhibition justifies the 
role in anticancer potential. 
Furthermore, there are increasing concerns about 
environmental effects, which require synthetic 
manipulation that minimize the use of hazardous 
chemicals. Many strategies have devised and 
investigated, mainly by replacing the traditional 
organic with other non-toxic solvents. Recently, ionic 
liquids have attracted broad interest as excellent 
alternatives to organic solvents, due to there desirable 
properties, such as non-flammability, no measurable 
vapour pressure, low toxicity, reusability, low-cost 
and high thermal stability34-38. In addition to the polar 
properties of ionic liquids, they are non-coordinating, 
which avoids any undesired solvent binding in pre-
transition states, and hence offers excellent 
advantages for asymmetric synthesis. As a result, 
ionic liquids considered promising alternative 
solvents for organic reactions. Over the past few 
years, these liquids have generated a significant 
amount of interest39-49. 
Result and Discussion 
In this study, we observed that substituted thiazole-
based β-amino carbonyl derivatives4d, 4g, 4i, 4k, 4l, 
4r, 4s, and 4u are more cytotoxic than the growth 
inhibition% compared with standard drug's CPT., 
ACV., CDDP., VBL., and TCT. Indifferent human 
cancer cell lines with several p53 statuses. Besides, 
asymmetric synthesis of various functional molecules 
is one of the essential tasks in modern organic 
synthesis50. Therefore, it is crucial to develop efficient 
a symmetric C-C bond forming reactions. 
The IR spectra of compounds 4a-u showed a  
peak at 3098-3150 cm−1 due to –NH function. A sharp 
band observed at 1680-1720 cm−1 corresponding  
to the carbonyl (-C=O) function derived from 
cyclohexanone structure. 
The 1H NMR spectra of compounds 4a-u displayed 
an additional signal at 6.53 ppm due to the –NH 
linkage derived from a thiazole moiety with aldehyde 
and cyclohexanone, while the sign due to the –NH2 
group of thiazole structure did not appear. The singlet 
for –OCH3 observed at 3.6 ppm integrated for three 
protons in 1H NMR spectra of compounds 4a-h. The 
1H NMR spectra of compounds 4i-p and 4q-u 
revealed singlets at 9.1 ppm and 1.3 ppm integrating 
for a single proton of –OH group and three protons of 
–CH3 group, respectively. Also, -OCH3 group of 
compound4b resonated at 3.84 ppm integrating for 
three protons as a singlet in the 1H NMR spectrum. 
Moreover, the signals derived from two –CH3 groups 
in compound 4c and 4j were recorded at 2.3 ppm 
integrating for three protons. A singlet at 9.1 ppm 
observed for the Ar –OH group of compound 4u.  
The 13C NMR spectrum of compound 4a showed 
aromatic resonances at 126.0, 129.4, and 151.7 for 
aromatic carbon atoms. Aromatic resonance’s signals 
for -Cl carbon appears at 162.32 for –OCH3, -OH, -
CH3 substitution and fused aldehydic aromatic  
carbon of compound 4a appears at 139.54, 134.14, 
130.44, 129.23, 126.51 and 115.48. The carbon of 
cyclohexanone ring found at 57.22, 39.52, 27.92, 
25.65, 23.65, respectively. The peak corresponding  
to the –OCH3 at 61.9 and the peaks at 62.9 and  
64.6 indicated the attachment of cyclohexanone ring 
via aromatic aldehyde with the formation of 
diastereomer arising from two unresolved chiral 
centres. The compounds 4a-u revealed peaks at 
211.0-217.3, suggesting the presence of -C=O of 
cyclohexanone ring.  




In this paper, we demonstrate an asymmetric 
Mannich-type reaction in ionic liquids (Scheme I). 
The elemental analysis and molecular ion peaks of 
compounds 4a-u were consistent with the assigned 
structure. The yield and melting point reported in 
Table I. 
 
Biological activity of the target molecules 
All compounds, as well as the standard drugs 
(Figure 1), were evaluated in vitro against a 2-cell line 
panel consisting of HCT116 and H1299 colon cancer 
cell lines, respectively. Results of all the substituted 
2-((4-phenyl)(4-(4-phenyl)thiazol-2-ylamino)methyl)-
cyclohexanone derivatives 4a-u are active, out of 
which most of the methoxy; hydroxy-phenylthiazole 
(4a-c, e-f, h, j, m) and methyl-phenylthiazole unit  
of substituted Mannich derivatives (4q, 4t) exhibited 
a weak inhibitory activity on the growth of  
HCT116. The H1299 cell line, all the compounds, 
shows promising activity. 2-(((4-(4-methoxyphenyl) 
thiazol-2(3H)-ylidene)amino)(3-nitrophenyl)methyl) 
cyclohexanone (4g) and 2-((4-chlorophenyl)((4-(p-
tolyl)thiazol-2(3H)-ylidene)amino)methyl)cyclohexanone 
(4r) were particularly active in both assays; 2-((3-
chlorophenyl)((4-(4-methoxyphenyl)thiazol-2(3H)-
ylidene)amino)methyl)cyclohexanone (4f) and 2-((4-
hydroxyphenyl)((4-(4-hydroxyphenyl)thiazol-2(3H)-
ylidene)amino)methyl)cyclohexanone (4o) were the 
least functioning; 4m and 4n are marginally  
active. The effect of all new compounds on colon 
cancer cell lines HCT116 and H1299 was observed, 
and results depicted in Figures 2-5. Growth inhibition 
% compared with standard drugs Camptothecin, 
Acyclovir, Cisplatin, Vinblastine, and Trichothecene. 
(Table II, Table III and Figures 6-7).  
 
Geometrical conformation 
The possible existence of the prepared compounds 
in various tautomeric forms represented in (Figure 8). 
 
 
Scheme I — One pot synthesis of thiazole based β-amino carbonyl derivatives 
 
 
Table I — Synthesis of compounds 4a-u 





4a OCH3 Cl H H 6 217 85 
4b OCH3 H H OCH3 6 190 89 
4c OCH3 H H N(CH3)2 6 185 87 
4d OCH3 H H F 6 188 85 
4e OCH3 H H Cl 6 195 84 
4f OCH3 H Cl H 6 245 84 
4g OCH3 H NO2 H 6 190 84 
4h OCH3 H H H 6 194 83 
4i OH H H OCH3 6 232 92 
4j OH H H N(CH3)2 6 212 86 
4k OH H H F 6 232 90 
4l OH H H Cl 6 235 90 
4m OH H Cl H 6 254 91 
4n OH H NO2 H 6 230 89 
4o OH H H OH 6 230 90 
4p OH H H H 6 258 82 
4q CH3 H H OCH3 6 130 85 
4r CH3 H H Cl 6 124 84 
4s CH3 H Cl H 6 125 83 
4t CH3 H NO2 H 6 125 84 
4u CH3 H H OH 6 126 83 
 














Figure 4 — Colon Cancer Cell (H1299) growth inhibition against compounds 4b-l 





In order to achieve better insight into the  
molecular structure of the most bioactive stereoisomer 
or tautomeric forms for compounds 4a-u, 
conformational analysis of the target compounds has 
been proposed (Figure 8). 
The tautomeric equilibrium clearly reveals that the 
central amino residue is in interaction with the keto 
group of cyclohexanone moiety. So, a significant 
impact on the binding energies and binding process 
 
Table III — Docking score (kcal/mole) of various anticancer 
drugs with APOBEC3B (PDB ID: 5QCD) 
S. No. Ligand Docking score 
(kcal/mole) 
1. Camptothecin - 5.9 
2. Acyclovir - 4.9 
3. Cisplatin - 2.8 
4. Trichothecin - 4.8 








Figure 6 — Colon Cancer Cell (HCT116) growth inhibition against standard anticancer drugs 
 
Table II — IC50 µg/mL of all synthesized compounds 4b-u
 4b 4c 4d 4f 4g 4i 4j 4k 4l 4m 4n 4o 4q 4r 4s 4t 4u 
HCT116 50 50 30 120 10 30 70 40 30 60 40 150 50 10 40 200 35 
H1299 25 20 40 80 8 30 40 40 30 30 35 150 30 20 70 35 5.5
 




interaction with bio target were observed (Table II). 
This could probably be due to the presence of 





Docking of the known anticancer drug in the active site of 
APOBEC3B (PDB ID: 5QCD) enzyme 
A comparative study involving the interaction of 
known anticancer viz. Camptothecin, Acyclovir, 
Cisplatin, Trichothecin, and Vinblastine ion the active 
site pocket of APOBEC3B made for a better 
understanding of there anticancer action. Docking 
score of these depicted in Table III 
In the case of APOBEC3B selective  
Vinblastine (Figure 9), the negative binding energies 
(-7.0 kcal/mol) are in agreement with its APOBEC3B 
selectivity as reported in several kinds of literature. 
Binding of Vinblastine in the binding pocket of 
APOBEC3B resulted from the conformational 
placement of amino acid residues in the active site 
and through hydrophobic interactions. 
There is a weak hydrogen bond of 2.88, 3.18, 3.19, 
and 3.22Å between the vinblastine carbonyl and three 
amino acid viz. Arg212, Trp281, and Gln213, as well 
as they, show hydrophobic interaction. The distal 
carbonyl oxygen and carbon of vinblastine show 
aromatic as well as allyl interaction with Tyr215, 
Arg211, and Phe237. 
Complexation of the docked ligand 4a-u and 
standard drugs with APOBEC3B enzyme was 
interpreted by looking at the H-bonding or 
hydrophobic interaction of the ligand with the amino 
acid residues in the active site. The results are 
summarized in Table IV. 
 
Docking of the synthesized ligand into APOBEC3B 
(PDB ID: 5CQD) active site 
All the twenty-one synthesized β-amino carbonyl 
derivatives showed binding in the 5CQD active site 
with binding scores between -5.8 and -6.6 kcal/mol, 
as shown in Table IV. The compelling data can  
be utilized further to develop potent anti-cancer 
heterocycles.  
 





















Figure 8 — Proposed tautomer structures of most stable stereoisomer compound 
 





Detailed 4t-5CQD structural interaction having 
the highest binding score among the other 
synthesized β-amino carbonyl derivatives 
From a consideration of the stereo view of 4t 
complexed inside the active-site gorge of 5CQD 
together with the LIGPLOT diagrams displayed in 
Figure 10, the following assignments can be made for 
protein-inhibitor interactions. 
The carbonyl oxygen of Gln213 shows 
hydrophobic interaction with the sulfur and carbon 
atoms of the thiazole ring along with this sulfur from 
thiazole interact with the aromatic ring of Tyr215. On 
top of communication, there is a weak hydrogen  
bond of 3.07Å between the carbonyl oxygen of  
the cyclohexanone chain with the primary amine  
of Gln213. Near the top of the gorge, the distal  
nitro group of 4t makes interaction with Tyr215  
 
 
Figure 9 — LIGPLOT Ligand (Vinblastine)-protein PDB ID- 5CQD interaction diagram 
  
Table IV — Docking score (kcal/mole) of different  
β-amino carbonyl analogue ligands 4a-u with APOBEC3B  
(PDB ID: 5CQD) 
S. 
No. 
Ligand Docking  
score 
(kcal/mol) 
S. No. Ligand Docking  
score 
(kcal/mol) 
1. 4a -5.8 12. 4l -5.9 
2. 4b -5.9 13. 4m -5.9 
3. 4c -5.9 14. 4n -6.2 
4. 4d -6.0 15. 4o -6.1 
5. 4e -5.9 16. 4p -5.9 
6. 4f -5.9 17. 4q -6.3 
7. 4g -6.2 18. 4r -6.4 
8. 4h -5.8 19. 4s -6.5 
9. 4i -6.0 20. 4t -6.6 
10. 4j -5.9 21. 4u -6.3 
11. 4k -6.0    
 




and a herringbone interaction with Gln213. At the 
bottom of the canyon and side amino acid, there is an 
aromatic-aromatic interaction between the proximal 
phenyl ring of 4t and Trp281 and the carbon  
and nitrogen atom of nitro-substituted aromatic 
carbon ring interact with Tyr215. The Arg211 and 
Arg212 show electrostatic interaction between the 
cationic meta carbon of nitrobenzene ring and 
cyclohexanone ring. 
The LIGPLOT diagrams in Figure 10 show atoms-
atoms contacts of ≤ 3.09Å made by the three 
inhibitors, viz. 4r, 4s, and 4t having the highest 
negative value compare with the other amino-acid 
residues lining the active site. The inhibitors show 
hydrophobic interaction with nearby side chains, as 
shown in red dashed. The red circles and ellipses in 
each plot designate protein residue that are 
corresponding 3D positions to the residues in the plot. 
The hydrogen bond is shown as green dotted lines, 
while the spoked arcs signify residues making 
nonbonded contact with the ligand. The highlighted 
equivalent side-chain residue has red underly beneath 
 
Figure 10 — Ligand-protein interaction diagrams for binding sites of the same protein APOBEC3B  
(PDB ID- 5CQD) each with a different ligand molecule having maximum negative binding value 




there bond and atoms. Equivalent waste engaged in 
hydrophobic interaction shown in thicker lines.  
 
Detailed study of Pharmacokinetics, 
Physicochemical, and Medicinal Properties by 
SwissADME online screening 
The operational highlights of these molecules 
entered in the SwissADME site (http://swissadme.ch) 
utilizing the ChemAxon's Marvin JS structure 
drawing instrument. Auxiliary highlights of a 
pharmacophore impact the conduct of a unit in 
people, including bioavailability, transport properties, 
empathy to proteins, reactivity, poisonous quality, and 
metabolic steadiness. Incomparable to swissADME is 
the bioavailability radar [51] that gives a graphical 
preview of the medication similarity parameters of an 
orally available bioactive drug. The drug resemblance 
diagram displayed as a hexagon (Figure 11) with each 
of the vertices speaking to a setting that characterizes 




Figure 11 — The bioavailability radar of the synthesized molecules (4a-u) and standard drugs (Camp., Acyc., 
Trich., Vinb.) evaluating using the swissADME web tool 




hexagon speaks to the ideal range for every property 
(lipophilicity: XLOGP3 between − 0.7 and + 5.0, 
size: polarity: TPSA somewhere in the range of 20 
and 130 Å, MW somewhere in the range of 150 and 
500 g/mol, solubility: log S not higher than 6, 
flexibility: close to 9 rotatable bonds, and saturation: 




The drug resemblance properties of the fused 
compound and standard drug are articulated to by the 
red mutilated hexagon inside the pink shade (Figure 
11). The 4b-d,g-k,n-p,t-u molecules fall within the 
drug-likeness parameter of a bioavailable drug. While 
4a,r,s shows outside parameters describe for 
lipophilicity and insolubility for bioavailability 
parameter and 4e,f,l,m have slightly outside the optical 
range of lipophilicity. (Figure 11). SwissADME 
likewise has computational channels that incorporate 
Ghose52, Egan53, Veber54, and Muegee55 created by top 
pharmaceutical organizations and cheminfomaticians 
to assess the drug resemblance of molecules.  
The Ghose screen quantitatively describes 
molecules dependent on figured physicochemical 
property profiles that incorporate log P, molar 
refractivity (MR), molecular weight (MW), and 
several atoms. The passing scope of determined log P 
(ClogP) is between -0.4 and 5.6. For MW, the moving 
extent is somewhere in the range of 160 and 480. For 
MR, the passing reach is somewhere in the range of 
40 and 130, and for the total number of atoms, the 
moving extent is between 20 and 70 atoms in a small 
molecule. Our compounds 4b,c, g-q, t-u, and out of 
four standard drugs tested only camptothecin qualify 
the Ghose qualifying criteria, but the molecule 
4a,e,f,r, and 4s out of the qualifying range (Table VI). 
Veber (GSK filter) model represents molecules as 
druglike on the off chance that they have ten or less 
rotatable bonds and a PSA equivalent to or under 140 
Å2 with 12 or less H-bond donors and acceptors.  
Egan (Pharmacia) filter gives an expectation of 
drug assimilation dependent on physical procedures 
engaged with film absorbency of a molecule. 
Significantly, the Egan computational model for 
human passive intestinal absorption (HIA) of 
 
Table V — Physicochemical properties of the synthesized molecules (4 a-u) and standard drugs(MW: Molecular weight; HA: Heavy 
atoms; AHA: Aromatic heavy atom; FCsp3: Fraction Csp3; RTB: Rotatable bonds; HBA: H-bond acceptors; HBD: H-bond  
donors; MR: Molar refractivity; TPSA: Total polar surface area). 
Sr. No. MW HA AHA FCsp3 RTB HBA HBD MR TPSA 
4a 426.96 29 17 0.3 6 3 1 119.77 79.46 
4b 422.54 30 17 0.33 7 4 1 121.25 88.69 
4c 435.58 31 17 0.36 7 3 1 128.97 82.7 
4d 410.5 29 17 0.3 6 4 1 114.72 79.46 
4e 426.96 29 17 0.3 6 3 1 119.77 79.46 
4f 426.96 29 17 0.3 6 3 1 119.77 79.46 
4g 437.51 31 17 0.3 7 5 1 123.58 125.28 
4h 392.51 28 17 0.3 6 3 1 114.76 79.46 
4i 408.51 29 17 0.3 6 4 2 116.79 99.69 
4j 421.56 30 17 0.33 6 3 2 124.5 93.7 
4k 396.48 28 17 0.27 5 4 2 110.25 90.46 
4l 412.93 28 17 0.27 5 3 2 115.3 90.46 
4m 412.93 28 17 0.27 5 3 2 115.3 90.46 
4n 423.48 30 17 0.27 6 5 2 119.12 136.28 
4o 394.49 28 17 0.27 5 4 3 112.32 110.69 
4p 378.49 27 17 0.27 5 3 2 110.29 90.46 
4q 406.54 29 17 0.33 6 3 1 119.73 79.46 
4r 410.96 28 17 0.3 5 2 1 118.25 70.23 
4s 410.96 28 17 0.3 5 2 1 118.25 70.23 
4t 421.51 30 17 0.3 6 4 1 122.06 116.05 
4u 392.51 28 17 0.3 5 3 2 115.26 90.46 
Camp 348.35 26 16 0.25 1 5 1 95.31 81.42 
Acyc 296.32 21 0 0.8 1 6 3 70.66 99.52 
Trich 225.2 16 9 0.38 4 5 3 55.68 119.05 
Vinb 810.97 59 15 0.59 10 11 3 232.52 154.1 
 




molecule represents dynamic carriage and efflux 
components and is, in this way, vigorous in foreseeing 
adaptation of drugs. The Egan violation only observed 
in 4n,r,s, and standard vinblastine drugs (Table VI).  
Muegge (Bayer filter) model is a database-free 
pharmacophore point screen that separates between 
drug-like and nondrug-like matter. It depends on the 
perception that non-drugs are frequently less 
functionalized. Four purposeful themes are 
characterized to be significant in drug-like molecules 
and incorporate hydroxyl, amine, ketone, and sulfonyl 
groups. In this manner, a base check of well-
characterized pharmacophore focuses is required to 
pass the screen. The manifestation of these efficient 
themes ensures hydrogen-holding capacities that are 
basic for explicit drug cooperation with its objectives. 
These serviceable groups can consolidate to what 
Muegge model alludes to as pharmacophore points. 
The pharmacophore emphases incorporate amine, 
amide, alcohol, ketone, sulfone, sulfonamide, 
carboxylic acid, carbamate, guanidine, amidine, urea, 
and active ester groups. These pharmacophore efforts 
in molecules possibly give critical communications 
with the objective protein. From the screening data, 
the synthesized compound 4a-h,l,m,q,r,s,t, and u that 
they don’t have the recommended functional group 
for the interaction with the target protein suggested by 
the Muegge.  
 
PAINS, Break and Leadlikeness screening 
PAINS (pan-assay interference screening) that 
often gives false favourable chemical properties 
results in high-throughput screens. PAINS tend  
to react non-specifically with numerous biological 
targets rather than specifically affecting one 
anticipated goal. 
PAINS (pan-assay interference screening) that 
regularly give false favourable synthetic properties 
bring about high-throughput screens. PAINS will, in 
general, respond non-specifically with various 
biological targets as opposed to explicitly influencing 
one anticipated objective. SwissADME evaluation did 
not post any PAINS alert except 4c and 4j molecules 
(Table VII).  
In another choice model, Brenk56 considered 
composites that are smaller and less hydrophobic and 
 
Table VI — Drug-likeness evaluation of synthesized compounds 
(4 a-u) using swissADME 










4a 0 1 0 0 1 
4b 0 0 0 0 1 
4c 0 0 0 0 1 
4d 0 1 0 0 1 
4e 0 1 0 0 1 
4f 0 1 0 0 1 
4g 0 0 0 0 1 
4h 0 0 0 0 1 
4i 0 0 0 0 0 
4j 0 0 0 0 0 
4k 0 0 0 0 0 
4l 0 0 0 0 1 
4m 0 0 0 0 1 
4n 0 0 0 1 0 
4o 0 0 0 0 0 
4p 0 0 0 0 0 
4q 0 0 0 0 1 
4r 0 1 0 1 1 
4s 0 1 0 1 1 
4t 0 0 0 0 1 
4u 0 0 0 0 1 
Camp 0 0 0 0 0 
Acyc 0 1 0 0 0 
Trich 0 1 0 0 0 
Vinb 2 3 1 1 4 
 
 
Table VII — Medicinal chemistry evaluation of the synthesized 
compounds 








4a 0 0 2 3.97 
4b 0 0 2 4.01 
4c 2 0 2 4.13 
4d 0 0 2 3.89 
4e 0 0 2 3.87 
4f 0 0 2 3.91 
4g 0 2 2 4.06 
4h 0 0 2 3.86 
4i 0 0 2 3.9 
4j 2 0 2 4.03 
4k 0 0 2 3.79 
4l 0 0 2 3.78 
4m 0 0 2 3.82 
4n 0 2 2 3.97 
4o 0 0 2 3.81 
4p 0 0 2 3.77 
4q 0 0 2 3.98 
4r 0 0 2 3.93 
4s 0 0 2 3.96 
4t 0 2 2 4.11 
4u 0 0 2 3.89 
Camp 0 0 0 3.84 
Acyc 0 1 0 5.42 
Trich 0 0 1 2.47 
Vinb 0 2 3 9.65 
 




not those characterized by "Lipinski's standard of 5"  
to enlarge open doors for lead streamlining. That  
was after the prohibition of compounds with  
possibly mutagenic, reactive, and unfavourable groups, 
for example, nitro, sulfates, phosphates, 2-
halopyridines, and thiols. Brenk model confines the 
ClogP/ClogD to sandwiched between zero and four, 
the quantity of hydrogen-bond donors and acceptors to 
less than 4 and 7, individually, and the number of 
substantial atoms to in the range of 10 and 27. 
Furthermore, just compounds with restricted 
entanglement characterized as less than eight rotatable 
bonds, less than five ring structures, and no ring 
structures with more than two fused rings are 
considered medicinal. The 4g,n, and 4t flouted two 
break rules by the presence of one nitro group, and 
standard Vinblastine also had two breaks.  
Leadlikeness tests are proposed to furnish leads 
with great kinship in high-throughput screens that 
take into account the detection and manipulation  
of new exchanges in the lead advancement stage 
(Table VII). The standard drugs camptothecin and 
acyclovir passed all the leadlikness criteria, while the 
synthesized compound with the standard 
trichothecene and vinblastine fail in leadlikness.  
 
P-glycoprotein and CYP enzyme activity 
prediction 
SwissADME additionally empowers the estimation 
for a compound to be a substrate of p-glycoprotein (P-
gp) or inhibitor of the cytochrome p450 isoenzymes 
(CYP isoenzymes). P-gp is broadly dispersed and 
communicated in the intestinal epithelium where it 
thrusts xenobiotics, for example, medicates over into 
the intestinal lumen and in the delicate endothelial 
cells making the blood-brain barrier where it propels 
them once again into the vessels. CYP isoenzymes are 
in charge of the biotransformation of drugs57. Drug 
digestion through CYP isoenzymes is a significant 
determinant of drug connections that can prompt to 
drug toxicities and diminished pharmacological 
impact. The models return "Yes" or "No" if the 
molecule under examination has a higher likelihood to 
be substrate or non-substrate of P-gp or inhibitor or 
non-inhibitor of a given CYP. The screening results 
are tabulated in Table VIII. 
 
Table VIII — Pharmacokinetic evaluation of the synthesized compounds (GI: gastro-intestinal absorption; BBB: blood-brain barrier; 



















4a High No Yes No Yes Yes Yes Yes 
4b High No Yes No Yes Yes Yes Yes 
4c High No Yes No Yes Yes Yes Yes 
4d High No Yes No Yes Yes Yes Yes 
4e High No Yes No Yes Yes Yes Yes 
4f High No Yes No Yes Yes Yes Yes 
4g Low No No No Yes Yes No Yes 
4h High No Yes Yes Yes Yes Yes Yes 
4i High No Yes Yes Yes Yes Yes Yes 
4j High No Yes Yes Yes Yes Yes Yes 
4k High No Yes Yes Yes Yes Yes Yes 
4l High No Yes Yes Yes Yes Yes Yes 
4m High No Yes Yes Yes Yes No Yes 
4n Low No Yes Yes Yes Yes No Yes 
4o High No Yes Yes Yes Yes Yes Yes 
4p High No Yes Yes Yes Yes Yes Yes 
4q High No Yes No Yes Yes Yes Yes 
4r High No Yes Yes Yes Yes No Yes 
4s High No Yes Yes Yes Yes No Yes 
4t Low No No Yes Yes Yes No Yes 
4u High No Yes Yes Yes Yes Yes Yes 
Camp High No Yes Yes No Yes No Yes 
Acyc High No Yes No No No No No 
Trich High No No No No No No No 
Vinb Low No Yes No No No No Yes 
 




HIA and BBB prediction 
Appropriate to P-gp and CYP protein energy is 
human gastrointestinal ingestion (HIA) and blood-
brain barrier infiltration (BBB). SwissADME 
'BOILED-Egg' (Figure 12) permits for assessment of 
HIA as an element of the situation of the molecules in 
the WLOGP-versus-TPSA referential. The white 
section of the 'BOILED-Egg' is for a high possibility 
of reflexive adaptation by the gastrointestinal tract, 
and the yellow area (yolk) is for a high probability of 
cerebrum entrance. Yolk and white zones are not 
fundamentally unrelated. With this, the points are 
shaded in blue whenever anticipated as effectively 
effluxed by P-gp (PGP+) and in red projected as non-
substrate of P-gp (PGP−). All the synthesized 
compound shows high GI absorption and no BBB 
prediction except 4g,t (red dot) and 4n they have the 
low GI and no BBB prediction. (Figure 12). 
HIA and BBB are subject to water solubility  
and lipophilicity of the drug. Two topological 
approaches to foresee water solubility comprised of 
SwissADME. The first is an execution of the ESOL58 
model, and the subsequent one modified from Ali 
et al.59. Swiss ADME third indicator for solubility 
was created by SILICON-IT. All anticipated qualities 
are the decimal logarithm of the molar solubility in 
water (log S). 
The Ali and Silicoms IT screening show poor 
solubility of all the synthesized compound while  
in ESOL solubility analysis most of the compounds 
are moderately soluble except 4a,f,r and s they  
show poor solubility (Table IX). Even the standard 
drugs are in the range of poor solubility to very 
soluble. Consensus Log p is the average value of all 




Figure 12 — The BOILED-Egg allows for evaluation of passive gastrointestinal absorption (HIA), brain
penetration (BBB) and P-glycoprotein in the presence of the molecule (P-gp) 





Every one of the reactions was conveyed  
under the stipulated conditions, utilizing freshly 
prepared thiazole, ionic liquid, and pure solvents. The 
open capillary technique was utilized to decide the 
dissolving purpose of the compound and are 
uncorrected. The refined dissolvable was utilized to 
perform TLC on silica gel G. All the synthetic 
compounds were bought from S.D. Fine synthetic 
substances of AR grade. 1H NMR and 13C NMR 
spectra recorded from DMSO-d6 arrangements on  
a Brucker AC 400 (MHz). TMS as an inward  
standard for detailing the substance move in 1H NMR. 
KBr plates strategy used to IR spectra on a Perkin 
Elmer 1800 spectrophotometer and mass spectra 
interpretation finished with a GC-MS (70ev).  
All tertiary alkyl amines concentrated H2SO4, 
cyclohexanone, and aromatic aldehydes obtained 
from S.D. Fine chemicals of AR grades.  
 
Procedure for 2-amino-4-(4-methoxyphenyl) 
thiazole2a49 
The title compound was set up by the expansion  
of resublimed iodine (0.01 moles) to 1-(4-
methoxyacetophenone (0.01 mol) and thiourea  
(0.02 mol), trailed by warming of the blend on a water 
bath at 100°C. The cooled reaction mixture was 
triturated with diethyl ether to evacuate any unreacted 
iodine and acetophenone. The solid residue was 
placed in cold water (250 mL) and treated with 
aqueous ammonium hydroxide. The precipitated 
thiazole was gathered and cleansed by crystallization 
from ethanol. The yield was 88%. 
 




The preparation of substituted β-amino carbonyl 
derivatives investigated in several ionic liquids. The 
 
Table IX — Water solubility evaluation of the synthesized compounds (Solu.: Solubility; PS: Poorly soluble; MS: Moderately soluble; S: 
soluble; VS: Very soluble) 
Sr. 
No. 
ESOL Ali Silicon-IT 













4a -6.18 2.83E-04 6.62E-07 PS -7.24 2.47E-05 5.77E-08 PS -8.39 1.72E-06 4.03E-09 PS 
4b -5.66 9.21E-04 2.18E-06 MS -6.76 7.38E-05 1.75E-07 PS -7.91 5.19E-06 1.23E-08 PS 
4c -5.82 6.54E-04 1.50E-06 MS -6.79 7.10E-05 1.63E-07 PS -7.88 5.72E-06 1.31E-08 PS 
4d -5.75 7.31E-04 1.78E-06 MS -6.7 8.21E-05 2.00E-07 PS -8.07 3.47E-06 8.45E-09 PS 
4e -6.18 2.83E-04 6.62E-07 PS -7.24 2.47E-05 5.77E-08 PS -8.39 1.72E-06 4.03E-09 PS 
4f -6.18 2.83E-04 6.62E-07 PS -7.24 2.47E-05 5.77E-08 PS -8.39 1.72E-06 4.03E-09 PS 
4g -5.65 9.73E-04 2.22E-06 MS -7.38 1.82E-05 4.16E-08 PS -7.15 3.10E-05 7.10E-08 PS 
4h -5.59 1.01E-03 2.57E-06 MS -6.6 9.97E-05 2.54E-07 PS -7.81 6.09E-06 1.55E-08 PS 
4i -5.45 1.46E-03 3.57E-06 MS -6.65 9.22E-05 2.26E-07 PS -7.22 2.46E-05 6.01E-08 PS 
4j -5.61 1.04E-03 2.47E-06 MS -6.68 8.88E-05 2.11E-07 PS -7.19 2.71E-05 6.43E-08 PS 
4k -5.54 1.15E-03 2.91E-06 MS -6.59 1.03E-04 2.59E-07 PS -7.38 1.64E-05 4.14E-08 PS 
4l -5.97 4.41E-04 1.07E-06 MS -7.14 3.01E-05 7.29E-08 PS -7.71 8.14E-06 1.97E-08 PS 
4m -5.97 4.41E-04 1.07E-06 MS -7.14 3.01E-05 7.29E-08 PS -7.71 8.14E-06 1.97E-08 PS 
4n -5.44 1.55E-03 3.65E-06 MS -7.27 2.28E-05 5.38E-08 PS -6.46 1.47E-04 3.48E-07 PS 
4o -5.24 2.27E-03 5.75E-06 MS -6.55 1.12E-04 2.85E-07 PS -6.53 1.16E-04 2.95E-07 PS 
4p -5.38 1.58E-03 4.19E-06 MS -6.48 1.24E-04 3.28E-07 PS -7.12 2.88E-05 7.62E-08 PS 
4q -5.89 5.25E-04 1.29E-06 MS -6.97 4.37E-05 1.07E-07 PS -8.19 2.66E-06 6.53E-09 PS 
4r -6.41 1.59E-04 3.86E-07 PS -7.46 1.43E-05 3.47E-08 PS -8.67 8.81E-07 2.14E-09 PS 
4s -6.41 1.59E-04 3.86E-07 PS -7.46 1.43E-05 3.47E-08 PS -8.67 8.81E-07 2.14E-09 PS 
4t -5.88 5.57E-04 1.32E-06 MS -7.59 1.08E-05 2.56E-08 PS -7.42 1.59E-05 3.78E-08 PS 
4u -5.68 8.29E-04 2.11E-06 MS -6.86 5.45E-05 1.39E-07 PS -7.49 1.26E-05 3.21E-08 PS 
Camp -3.49 1.14E-01 3.27E-04 S -3.07 2.99E-01 8.58E-04 S -5.83 5.20E-04 1.49E-06 MS 
Acyc -1.16 2.06E+01 6.96E-02 VS -0.89 3.78E+01 1.28E-01 VS -0.81 4.59E+01 1.55E-01 S 
Trich -0.41 8.85E+01 3.93E-01 VS -0.43 8.32E+01 3.69E-01 VS -1.28 1.19E+01 5.28E-02 S 
Vinb -6.84 1.17E-04 1.44E-07 PS -6.81 1.25E-04 1.54E-07 PS -8.46 2.80E-06 3.45E-09 PS 
 




choices of ionic liquids were motivated by there being 
the most widely used, and therefore the most widely 
available50. 
 
Biological Assay  
 
In vitro anticancer assays 
In this assay, the viability of chemically treated cells 
measured by a dye, Resazurin, or Alamar blue (AB). 
AB, a non-fluorescent marker colour, is changed over 
to brilliant red– fluorescent resorufin employing the 
reduction reactions of metabolically dynamic cells. The 
quantity of living cells is legitimately corresponding to 
the measure of fluorescence delivered. 
 
Protocol:  
1 Trypsinize the cell and dilute with RPMI medium 
(with 5% serum)  
2 Count the cells and dilute them in the same  
RPMI medium. 
3 Add 100,000 cells per well in 40 µL. Use 384 
well black plates. 
4 Make a 2X solution for each dilution in the  
RPMI medium and add 50µL per well. Use 
appropriate positive and negative controls. 
5 Add 10 µL Alamar blue and incubate ON.  
6 Measure Fluorescence. (560nm / 590 nm  
Ex/Em). The contrast in fluorescence intensity 
estimates the counter cancer impact of that 
compound. 
Sample (5 mg) was dissolved in 250 µL DMSO to 
achieve a concentration of 20 mg/mL. In each well, 
100 µL medium with cells was added and allowed to 
grow overnight so that cells attained a limit of 10.000 
cells / well. Two cell lines HCT116 (Mismatched 
DNA repair deficiency) and H1299 (P53 deficient). 
The supernatant medium discarded, and 100 µL of 
fresh medium added. The top of the well had 125 µL 
of the solution; 2.5 µL of stock solution added. The 
net concentration of the cells was 400 µg/mL. The 
material was inserted into the second row of the 
microtiter plates and sequentially diluted to 1/5: a 
total of six dilutions made. The 7th and 8th rows used 
as controls. The plates incubated for 48 hours, and the 
supernatant discarded. Fresh medium containing 2% 
Alomar Blue added. Further incubation of 2 hours 
was followed by a reading of the fluorescence 
intensity. The active cells released the fluorescence; 
the intensity was directly proportional to the number 
 
Table X — lipophilicity evaluation of the synthesized compounds 
Sr. No. iLOGP XLOGP3 WLOGP MLOGP Silicos-IT Log P Consensus Log P 
4a 3.67 5.8 5.87 3.54 6.45 5.07 
4b 3.67 5.15 5.22 2.71 5.88 4.53 
4c 3.85 5.3 5.28 2.92 5.5 4.57 
4d 3.68 5.28 5.78 3.44 6.24 4.88 
4e 3.82 5.8 5.87 3.54 6.45 5.1 
4f 3.74 5.8 5.87 3.54 6.45 5.08 
4g 3.32 5.01 5.12 2.1 3.65 3.84 
4h 3.65 5.18 5.22 3.06 5.82 4.59 
4i 3.28 4.82 4.92 2.5 5.33 4.17 
4j 3.25 4.97 4.98 2.71 4.96 4.17 
4k 3.2 4.95 5.47 3.23 5.7 4.51 
4l 3.11 5.48 5.57 3.33 5.92 4.68 
4m 3.3 5.48 5.57 3.33 5.92 4.72 
4n 2.75 4.68 4.82 1.89 3.1 3.45 
4o 2.82 4.5 4.62 2.29 4.8 3.81 
4p 3.02 4.85 4.91 2.85 5.29 4.18 
4q 3.96 5.54 5.52 3.28 6.34 4.93 
4r 4.01 6.2 6.17 4.13 6.92 5.49 
4s 3.95 6.2 6.17 4.13 6.92 5.47 
4t 3.23 5.4 5.42 2.63 4.11 4.16 
4u 3.14 5.21 5.22 3.06 5.8 4.49 
Cam 2.49 1.74 1.82 1.64 3.29 2.2 
Acy 1.78 -0.72 -0.84 -0.74 0.8 0.06 
Tric 0.48 -1.56 -1.48 -1.43 -0.57 -0.91 
Vin 5.06 3.88 2.85 2.35 4.72 3.77 
 




of cells. Both HCT116 and H1299 are colon cancer 
cell lines obtained from ATCC. HCT116 is a 
mismatch repair-deficient cell line, and H1299 has a 
p53 mutation. 
 
In vitro anti-cancer activity 
Standard Alamar Blue Assay protocol for Cell 
viability assay used. Coherently developed cells were 
trypsinized, and around 10,000 cells seeded in each 
well of 96 well plates. The next day the medium was 
supplanted with medium containing suitable 
centralization of the drug. Compounds were 
suspended in 250 µL DMSO, and 2.5 µL added to 
each well in 125 µL, 1/5 dilution up to 5 dilutions for 
HCT116/H1299 Cancer cell line. The maximum 
concentration of each drug is 400 µg/mL, 1/5 dilution 
used for each drug. The cells treated for 48 hours and 
2 µL of Alamar blue was added to each well and 
brooded for two hours. Fluorescence intensity read 
with a plate reader. The IC50 value was calculated 
from the graph.  
 
Computational Details 
All the ligand used was made using ChemDraw 3D 
60. Before the docking calculation of the ligands, the 
structure was lower in energy and then docked by 
using PyRx61. The crystal structure for the complex 
with an inhibitor downloaded from Protein Data Bank 
(http://www.rscb.org/) as a PDB file. The active site 
of the docked protein was found out by Argus Lab 
4.062, which used for the docking in the PyRX.  
The downloaded protein of the Cancer Genomic 
DNA Mutator APOBEC3B (PDB ID- 5CQD) contain 
chain A and C with Glycerin; Propane-1,2,3-triol and 
zinc ion as interacting ligand. The selected chain A 
contains 185 residues having twenty-six active site 
viz. Arg211, Arg212, Arg257, Asn240, Asp346, 
Cys239, Cys284, Cys289, Gln213, Glu241, Glu255, 
Glu342, His253, Leu238, Leu318, Met186, Phe237, 
Phe285, Pro283, Ser286, Thr214, Trp281, Trp287, 
Tyr191, Tyr215 and Tyr313. The chain A and C with 
the residues, water, and hetero group within a radius 
of 2.08A° refined for further cleaned by ascertaining 
the hybridization and introducing the H-atoms to the 
protein residue with the removal of water molecules. 
The cleaned structure of the Cancer Genomic DNA 
Mutator APOBEC3B (PDB ID- 5CQD) chain A 
carried no charge, 1356 valence electron, and 496 
atoms. The docking with PyRx (Autodock) was 
conducted vina search space of dimension size x = 
45.9667083596, y = 33.1205244125, z = 
34.2302049496; center x = 73.3676401887, y = 
4.22414666002, z = 0.401404471846 with nine 
exhaustiveness. The best conformational binding 
energy reported in Table VI. The LIGPLOT+ version 
V.1.4.563 was used to find the multiple ligand-protein 
interaction diagram.  
 
Conclusion 
All compounds were evaluated in vitro against a 
two-cell line panel consisting of HCT116 and H1299, 
respectively. Results indicate that all the substituted 
2-((4-phenyl)(4-(4-phenyl)thiazol-2-ylamino)methyl) 
cyclohexanone derivatives 4a-u are active.  
From the graphical representation, it can conclude 
that the compounds 4b,c and q moderate repressive 
while the 4j,m weak inhibitory activity, and 4f,o and t 
have very less action against but out of which 4g, r 
shows proposing an operation against a cancer cell 
line HCT116. In case activity against H1299 cell 
lines,4g shows excellent activity while the others  
are moderate activity. The compound 4r, 4s, and 4t 
show comparable binding energy score with the 
standard drug-like Vinblastine (-7.0kcal/mol) and 
higher as compare to Camptothecin (-5.9 kcal/mol). 
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